Status:
COMPLETED
Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia
Lead Sponsor:
New York Presbyterian Hospital
Conditions:
Cervical Dysplasia
Eligibility:
FEMALE
18-80 years
Phase:
PHASE3
Brief Summary
To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwi...
Detailed Description
To determine if the use of oral Diindolylmethane (DIM), a marketed cruciferous vegetable based dietary supplement (BioResponse-DIM®), is associated with the regression of cervical dysplasia in otherwi...
Eligibility Criteria
Inclusion
- Non pregnant women greater than or equal to 18 years of age able to consent
- CIN II or III confirmed by histology
- Karnofsky performance status \>= 80
- No prior treatment for dysplasia in the past 4 months
Exclusion
- Incompletely visible lesion
- Diethylstilbestrol (DES) exposure
- HIV seropositive
Key Trial Info
Start Date :
September 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00212381
Start Date
September 1 2000
End Date
July 1 2010
Last Update
March 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU School of Medicine
New York, New York, United States, 10016